New! View global litigation for patent families

US20020049247A1 - Novel treatment for eye disease - Google Patents

Novel treatment for eye disease Download PDF

Info

Publication number
US20020049247A1
US20020049247A1 US09760362 US76036201A US2002049247A1 US 20020049247 A1 US20020049247 A1 US 20020049247A1 US 09760362 US09760362 US 09760362 US 76036201 A US76036201 A US 76036201A US 2002049247 A1 US2002049247 A1 US 2002049247A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
photosensitizing
light
compound
method
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09760362
Inventor
James Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Light Sciences Corp
Original Assignee
Light Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic

Abstract

This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.

Description

    RELATED APPLICATIONS
  • [0001]
    This application claims the benefit of U.S. application Ser. No. 60/175,689, filed Jan. 12, 2000. This application is also related to the PCT application entitled “Novel Treatment for Eye Disease,” Inventor James C. Chen, attorney docket number 398032000940, filed on even date herewith. Each of these applications is incorporated by reference herein in its entirety as if fully set forth below.
  • TECHNICAL FIELD
  • [0002]
    This invention relates generally to the field of medicine and pharmacotherapeutics with photosensitizing agents or other energy activated agents. Specifically, this invention relates to kits and methods useful for the treatment of neovascular diseases of the eye. The invention involves the site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time.
  • BACKGROUND ART
  • [0003]
    Neovascular diseases of the eye include diabetic retinopathy, age-related macular degeneration and neovasculature growth induced by angiogenic factors or resulting from tumor cells, themselves. Diabetic retinopathy is characterized by a number and variety of microvascular changes which can result ultimately in adverse visual changes and vision loss. In many cases the microvascular changes are due to or associated with upregulation of angiogenesis receptors and factors or ligands which lead to new vessel formation, changes in vascular permeability, and possibly other alterations in vessel morphology. These changes may lead to hemorrhage, edema, ischemia, and other problems resulting in vision dysfunction (see: Aiello et al., Diabetes Care, 21:143-156, 1998).
  • [0004]
    Treatments for the various forms of, and problems associated with, diabetic retinopathy include laser photocoagulation, vitrectomy, cryotherapy, and membranotomy. All of these clinical therapies and procedures are associated with problems and side effects. For example, the side effects and complications related to panretinal laser photocoagulation, the most common present treatment for diabetic retinopathy, include: decreased visual acuity, increased macular edema, transient pain, exudative retinal detachment, and inadvertent foveolar bums.
  • [0005]
    Age-related macular degeneration (“AMD”) is the leading cause of blindness in the United States among individuals 65 or older. One form of AMD is characterized by formation of choroidal neovessels which can lead to a number of pathologic conditions resulting in visual dysfunction and loss. As with diabetic retinopathy, angiogenesis plays a key role in the formation of these neovessels. The proliferation of choroidal neovessels associated with AMD can contribute to irreversible damage of photoreceptors. Thus, current treatment of AMD, like that of diabetic retinopathy, involves the use of laser photocoagulation. However, because photocoagulation relies upon the gross thermal destruction of the choroidal neovascular tissue, damage to the retina and surrounding choroidal tissue often results. Furthermore, recurrences after photocoagulation therapy are common. (see: Schmidt-Erfurth et al., Greafe's Arch Clin Exp Opthamol, 236:365-374, 1998).
  • [0006]
    As an alternative to photocoagulation, photodynamic therapy has been proposed as a means of treating this form of AMD (see: Strong et al., “Vision through photodynamic therapy of the eye,” U.S. Patent Nos. 5,756,541 and 5,910,510; and Mori et al., “Photochemotherapeutical obstruction of newly-formed blood vessels,” U.S. Patent No. 5,6333,275). Photodynamic therapy (“PDT”), as taught in this prior art, is a two-step treatment process. PDT is performed by first administering a photosensitive compound systemically or topically, followed by illumination of the treatment site at a wavelength or waveband of light from a laser which closely matches the absorption spectra of the photosensitizer. In doing so, singlet oxygen and other reactive species are generated leading to a number of biological effects resulting in damage to the endothelial membranes and ultimately to clotting of the neovasculature.
  • [0007]
    Although this form of PDT represents an improvement over photocoagulation, clinical experience has established that the therapy must be repeated on a regular basis, typically every 3 months due to regrowth of the vessels (see: Schmidt-Erfurth et al.). The regrowth is believed to be due to upregulation of angiogenic factors and/or receptors secondary to the relative ischemia caused by the PDT treatment as outlined in the prior art. Clearly there is a need for a therapy which reduces the number of treatments which probably need to be performed for the rest of the patient's life.
  • [0008]
    In addition to neovascular tissue formation associated with diabetic retinopathy and age-related macular degeneration, the growth of new blood vessels are also associated with tumor formation in the eye, which results from two mechanisms: the stimulated growth of endothelial cells of existing blood vessels through angiogenesis; and a newly discovered vasculature resulting from highly malignant uveal melanomas, which develop in the eye, are full of networks of blood channels made by the melanoma cells themselves (Maniotis et al., American Journal of Pathology 155(3): 739-52 (1999)). It may be that anti-angiogenic agents are ineffective in the treatment of such neovasculature arising not from endothelial cells, but from tumor cells such as those of malignant uveal melanomas.
  • [0009]
    Furthermore, because current PDT methods involve the systemic administration of untargeted photosensitive compounds or photosensitizers, the required dosages are relatively high which can lead to skin photosensitivity. The accumulation of photosensitizers in the skin is a property of all systemically administered sensitizers in clinical use. For example, clinically useful porphyrins such as Photophrin® (QLT, Ltd. brand of sodium porfimer) are associated with photosensitivity lasting up to 6 weeks. Purlytin®, which is a purpurin, and Foscan®, a chlorin, sensitize the skin for several weeks. Indeed, efforts have been made to develop photoprotectants to reduce skin photosensitivity (see: Dillon et al., Photochemistry and Photobiology, 48(2): 235-238, 1988; and Sigdestad et al., British J of Cancer, 74:S89-S92, 1996). In fact, PDT protocols involving systemic administration of photosensitizer require that the patient avoid sunlight and bright indoor light to reduce the chance of skin phototoxic reactions.
  • [0010]
    While there are reports in the scientific literature describing the use of ligand-receptor binding pairs, that literature is primarily drawn to the treatment of malignant tumor cells. There are a few reports that address the treatment of eye-related neovascular diseases such as diabetic retinopathy and AMD. However, either these reports fail to disclose the use of PDT at all or these reports fail to teach the use of such methods in conjunction with the targeting of blood vessels (see, for example: Savitsky et al., SPIE, 3191: 343-353, 1997; Ruebner et al., SPIE, 2625: 328-332, 1996; Reno et al., U.S. Pat. No. 5,630,996; Casalini et al., J Nuclear Med., 38(9): 1378-1381, 1997; Griffiths, U.S. Pat. No. 5,482,698; and Mew et al., J of lmmunol., 130(3): 1473-1477, 1983). It should be noted that even though Strong et al. U.S. Patent Nos. 5,756,541 and 5,910,510 suggest that a photoactive agent may be coupled to a specific binding ligand which may bind to a specific surface component of the target ocular tissue, there is little guidance provided to suggest appropriate ligands effective in such PDT methods.
  • [0011]
    Regarding light sources for PDT, high powered lasers are usually employed in order to shorten the procedure time (see: Strong et al., U.S. Patent Nos. 5,756,541and 5,910,510; and Mori et al., U.S. Patent No. 5,6333,275; see more generally, W. G. Fisher, et al., Photochemistry and Photobiology, 66(2):141-155, 1997).
  • [0012]
    However, the present art lacks an effective method of treating neovasculature diseases of the eye using a PDT methodology, which reduces damage to collateral or healthy tissue and which does not expose the tissue of the eye to intense laser light. The present art further teaches the need for recurrent treatment, the need for which is thought to arise, as discussed above, due to upregulation of angiogenic factors and/or receptors secondary to the relative ischemia caused by the PDT treatment as outlined in the prior art. Clearly there is a need for a therapy which reduces the number of treatments which probably need to be performed for the rest of the patient's life.
  • [0013]
    Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. Further, all documents referred to throughout this application are incorporated in their entirety by reference herein.
  • SUMMARY OF THE INVENTION
  • [0014]
    The present invention describes methods to treat neovascular disease of the eye based on the precise targeting of photosensitive compounds to target tissue and the activation of these targeted photosensitizer compounds by subsequently administering to the subject non-coherent (non-laser) or coherent (laser) light of a relatively low fluence rate over a prolonged period of time.
  • [0015]
    The present invention further discloses the selective binding of the photosensitizing agent to specific receptors and/or antigens present on abnormal endothelium or to specific ligands and/or antibodies which are themselves bindable to endothelial receptors and antigens. This targeting scheme decreases the amount of sensitizing drug required for effective therapy, which in turn reduces the fluence rate or light irradiation needed for effective photoactivation. As a result, the disclosed method achieves maximal dosage to abnormal endothelium with minimal side effects or collateral tissue damage.
  • [0016]
    Additionally, the present disclosure teaches the unexpected use of a low power non-coherent light source utilized for longer than about 4 minutes. This teaches away from the use of a high powered, brief exposure using laser light, results in fuller, more efficient activation of the bound photosensitizers, and enables a high therapeutic index using a low dose drug. Moreover, a low power non-coherent light source is relatively inexpensive and simpler to use. Finally, because the present invention teaches photoactivation with a non-coherent, broadband light source, different types of photosensitizers can be activated with a single light source.
  • [0017]
    Due to the highly specific nature of the photosensitizer uptake, excess light or light falling on nonpathologic areas causes no unwanted photoactivation. Therefore, a region of the retina or macular with diffuse abnormalities can be safely treated without damaging intervening normal eye structures. In addition, eye movement by the patient during treatment, which can result in the further exposure to light of normal eye structures, is harmless. Thus, the use of highly targeted photosensitizers allows the delivery of light in a diffuse fashion and over a prolonged illumination period. In fact, one embodiment of the invention is the use of ambient light to activate the photosensitized neovascular tissue.
  • [0018]
    Further, the binding of the photosensitizer/ligand conjugate to the endothelial receptor, as taught by the present invention, causes blockage and/or down regulation of the receptor which further inhibits neovessel formation and subsequent regrowth of neovasculature, which generally results from more traditional methods of PDT. Similarly, the use of a photosensitizer/receptor conjugate would serve to bind circulating ligands also inhibiting neovessel formation. This added benefit of the present invention operates independently of the light-activated vessel occlusion described above.
  • [0019]
    An embodiment of the present invention is drawn to a method for photodynamic therapy (“PDT”) of neovascular disease of the eye comprising: administering to the subject a therapeutically effective amount of a photosensitizing compound, where the photosensitizing compound selectively binds to the target abnormal endothelium that lines or composes the neovasculature target tissue. This step is followed by illuminating the neovasculature tissue with light at a wavelength or waveband absorbed by the targeted photosensitizing compound where the light is provided by a non-laser light source, and for a period of time sufficient to activate the photosensitizing compound thereby causing damage to the neovasculature target tissue. In this embodiment of the present invention, the targeted photosensitizing compound is cleared from non-target tissues of the subject prior to irradiation.
  • [0020]
    A preferred embodiment of the present invention is drawn to a method for PDT of neovascular disease of the eye as described above, wherein the neovascular target tissue is present in the retina, choroid or both of a subject diagnosed with diabetic retinopathy or age-related macular degeneration (“AMD”). A further preferred embodiment of this invention provides a method for PDT of neovascular tissue associated with tumor formation in the eye, and more specifically neovascular tissue resulting from angiogenesis or growth factors elicited by tumors, such as malignant uveal melanomas.
  • [0021]
    A more preferred embodiment of the present invention is drawn to a method of PDT of neovascular disease of the eye as described above, wherein the targeted photosensitizing compound is bound to a first component of a bindable pair and wherein the second component of the bindable pair is selected from the group consisting of: receptor present on abnormal endothelium; ligand bindable to receptor present on abnormal endothelium; antigen present on abnormal endothelium; and antibody bindable to antigen present on abnormal endothelium.
  • [0022]
    Yet another preferred embodiment contemplates a method of PDT of neovascular disease of the eye as described above, where the ligand is selected from the group consisting of: VEGF; VEGF receptor; and α-3, β-3 integrin receptor. A further preferred embodiment provides a method of PDT of neovascular disease of the eye, where the ligand comprises an antibody specific or having a high degree of affinity for the extra-domain B (or ED-B) of fibronectin. An even more preferred embodiment is drawn to the ligand discussed above, which is a complete or functional bindable fragment of a human antibody, such as L19 or its equivalent (see: Birchler et al., Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment, Nature Biotech. 17: 984(1999)).
  • [0023]
    Another preferred embodiment of the present invention is drawn to a method of PDT of neovascular disease of the eye as described above, where the targeted photosensitizing compound is bound to a receptor composition that mimics a receptor present on abnormal endothelium.
  • [0024]
    Another preferred embodiment of the present invention is drawn to a method of PDT of neovascular disease of the eye as described above, where the targeted photosensitizing compound is bound to a bi-specific antibody construct that further comprises both a ligand component and a receptor component.
  • [0025]
    A still further embodiment of the present invention is drawn to a method of PDT of neovascular disease of the eye as described above, where the targeted and bound photosensitizing compound is incorporated into a liposomal preparation.
  • [0026]
    The invention also provides kits comprising any of the components that are used in PDT of neovascular disease as taught herein and instructions (such as an instruction sheet or computer disk) that teach the methods described herein.
  • [0027]
    The invention also provides methods of teaching a person to conduct treatments of neovascular disease, where the methods comprise instructing a person to conduct the PDT methods described herein.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0028]
    [0028]FIG. 1 illustrates three types of bound photosensitizing compounds: ligand construct, receptor construct, and bispecific antibody construct.
  • [0029]
    [0029]FIG. 2 illustrates a photosensitizing compound incorporated into a liposomal preparation that includes a ligand construct, receptor construct, and bispecific antibody construct.
  • [0030]
    [0030]FIG. 3 shows an eye subjected to ambient light and collimated LED light.
  • [0031]
    [0031]FIG. 4 shows a lateral view of skull (partial) with placement of LED light sources.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0032]
    This invention provides methods for treating neovascular disease of the eye by the specific and selective binding of a photosensitizing compound to the abnormal endothelium that lines or composes the neovasculature target tissue. This method comprises illuminating the photosensitized target tissue with light for a period of time sufficient to activate the bound photosensitizing compound thereby causing damage to the neovasculature target tissue.
  • [0033]
    Specifically, the present invention is based on the precise targeting of photosensitizing compounds to specific target receptors and/or antigens present on abnormal endothelium or to specific ligands and/or antibodies which are themselves bindable to endothelial receptors and antigens, and to the method of activation of the bound and targeted photosensitizing compounds by subsequently administering to the target tissue light of a relatively low fluence rate over a prolonged period of time. The disclosed method achieves maximal damage to abnormal endothelium with minimal side effects or collateral tissue damage.
  • [0034]
    Terms as used herein are based upon their art recognized meaning and from the present disclosure should be clearly understood by the ordinary skilled artisan. For sake of clarity, terms may also have particular meaning as would be clear from their use in context.
  • [0035]
    Further, as used herein, “target tissues” are those tissues that are intended to be impaired or destroyed by this treatment method. Photosensitizing compounds bind to these target tissues; then when sufficient radiation is applied, these tissues are impaired or destroyed.
  • [0036]
    “Non-target tissues” are all the tissues of the eye which are not intended to be impaired or destroyed by the treatment method. These non-target tissues include but are not limited to healthy blood cells, and other normal tissue of the retina and choroid, not otherwise identified to be targeted.
  • [0037]
    “Photosensitizing compound” is a chemical compound which homes to one or more types of selected target cells and, when contacted by radiation, absorbs the light, which results in impairment or destruction of the target cells. Virtually any chemical compound that homes to a selected target and absorbs light may be used in this invention. Preferably, the chemical compound is nontoxic to the subject to which it is administered or is capable of being formulated in a nontoxic composition. Preferably, the chemical compound in its photodegraded form is also nontoxic. A comprehensive listing of photosensitive chemicals may be found in Kreimer-Bimbaum, Sem. Hematol. 26:157-73, 1989. Photosensitive compounds include, but are not limited to, chlorins, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD) and porfimer sodium and pro-drugs such as δ-aminolevulinic acid, which can produce drugs such as protoporphyrin. Other compounds include indocyanine green (ICG); methylene blue; toluidine blue; texaphyrins; and any other agent that absorbs light in a range of 500 nm -1100 nm.
  • [0038]
    “Illumination” as used herein includes all wave lengths and wavebands. Preferably, the illumination wave length or waveband is selected to match the wave length(s) or wavebands which excite the photosensitive compound. Even more preferably, the radiation wave length or waveband matches the excitation wave length or waveband of the photosensitive compound and has low absorption by the non-target tissues of the eye, and the rest of the subject, including blood proteins.
  • [0039]
    The irradiation by illumination is further defined in this invention by its coherence (laser) or non-coherence (non-laser), as well as intensity, duration, and timing with respect to dosing using the photosensitizing compound. The intensity or fluence rate must be sufficient for the light to reach the target tissue. The duration or total fluence dose must be sufficient to photoactivate enough photosensitizing compound to act on the neovasculature target tissue. Both intensity and duration must be limited to avoid overtreating the subject. Timing with respect to dosing with the photosensitizing compound is important, because 1) the administered photosensitizing compound requires some time to home in on neovasculature target tissue and 2) the blood level of many photosensitizing compounds decreases with time.
  • [0040]
    Briefly, the photosensitizing compound is generally administered to the subject before the neovasculature target tissue is subjected to illumination.
  • [0041]
    Preferred photosensitizing compounds include, but are not limited to, chlorins, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens and pro-drugs such as δ-aminolevulinic acid, which can produce drugs such as protoporphyrin. More preferred are: methylene blue; toluidine blue; texaphyrins; and any other agent that absorbs light in a range of 600 nm -1100 nm. Most preferred is indocyanine green (for example, see: WO 92/00106 (Raven et al.); WO97/31582 (Abels et al.) and Devoisselle et al., SPIE 2627:100-108, 1995). Additional photosensitizing compounds, include: pyropheophorbide compounds (see: U.S. Patent No.: 5,459,159); bacteriochlorophyll derivatives (see: U.S. Patent No.: 5,955,585); and Alkyl ether analogs of chlorins (see: U.S. Patent No.: 5,952,366).
  • [0042]
    Any one or combination of these or other photosensitizing compounds may be supplied in a kit of this invention along with instructions on conducting any of the methods disclosed herein. Instructions may be in any tangible form, such as printed paper, a computer disk that instructs a person how to conduct the method, a video cassette containing instructions on how to conduct the method, or computer memory that receives data from a remote location and illustrates or otherwise provides the instructions to a person (such as over the Internet). A person may be instructed in how to use the kit using any of the instructions above or by receiving instructions in a classroom or in the course of treating a patient using any of the methods disclosed herein, for example.
  • [0043]
    The photosensitizing compound is administered orally, intravenously by injection, or via the intraocular route. The photosensitizing compound can be conjugated to various antibodies, antibody fragments, and other molecules and compounds capable of binding to the endothelium of neovessels. The specific ligands reactive with the target endothelium include antibodies and antibody fragments that bind to abnormal or upregulated vascular endothelial receptors such as the VEGF receptors and α-3, β-3 integrins (see: Ferrara, Curr Top Microbiol Immunol, 237:1-30, 1999; Elicieri and Cheresh, The Journal of Clinical Investigation, 103:1227-30, 1999; Smith et al., Br J Opthamol, 83:486-494, 1999). Also, the antibody can be drawn to and have affinity to bind to the extra-domain B (or ED-B) of fibronectin. Such antibodies, include a complete or functional bindable fragment of a human antibody, such as L19 or its equivalent (see: Birchler et al., Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment, Nature Biotech. 17: 984 (1999)). The ligand can be any molecule or compound that binds to a endothelial receptor found on an abnormal blood vessel wall. Preferably the ligand binds selectively to receptors which are mainly or only found on the abnormal blood vessel wall.
  • [0044]
    Another embodiment of the present invention involves the use of a photosensitizing compound bound to a receptor-type molecule or compound. The receptor mimics the type of receptors found on the endothelium of abnormal vessel walls. Preferably the receptor mimic binds ligands, such VEGF, that are found to be elevated in concentration or are not normally present due to the abnormal conditions relating to the abnormal blood vessel formation. An additional embodiment involves the use of a bispecific antibody construct that is a combination ligand and receptor type molecule or compound that is bound to a photosensitizing compound. The bispecific nature of this construct allows binding of either an abnormal endothelial receptor or an abnormal ligand or abnormally elevated concentration of ligand.
  • [0045]
    Alternatively, the photosensitizing compound can be packaged into liposomes and the ligand, receptor, or bispecific construct incorporated or attached to the liposome to serve as a further means of targeting. In each of the above embodiments, preferably more than one photosensitizing compound is attached to the targeting moiety.
  • [0046]
    The technique of constructing bispecific antibodies, the techniques and methods of linking photosensitizers to targeting agents, and the techniques of producing targeted liposomes are well known in the art. For example, useful reviews of such techniques are provided by Yatvin et al., U.S. Patent No. 5,827,819 (1998) and Jansen, et al., U.S. Patent No. 5,869,457 (1999).
  • [0047]
    The bound photosensitizing compound can be administered in a dry formulation, such as pills, capsules, suppositories or patches. The compound also may be administered in a liquid formulation, either alone with water, or with pharmaceutically acceptable excipients, such as are disclosed in Remington's Pharmaceutical Sciences. The liquid formulation also can be a suspension or an emulsion. In particular, liposomal or lipophilic formulations are desirable. If suspensions or emulsions are utilized, suitable excipients include water, saline, dextrose, glycerol, and the like. These compositions may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, antioxidants, pH buffering agents, and the like.
  • [0048]
    The dose of photosensitizing compound can be determined clinically and will be the lowest dose that saturates the available binding sites. Depending on the photosensitizing compound used, an equivalent optimal therapeutic level will have to be established. A certain length of time is allowed to pass for the circulating or locally delivered photosensitizer to be taken up by the endothelium of the neovessels. The unbound photosensitizer is cleared from the circulation during this waiting period. The waiting period will be determined clinically and may vary from compound to compound.
  • [0049]
    At the conclusion of this waiting period, a non-laser light source is used to activate the bound drug, although a laser light source may be used. The spot size illuminating the retina or choroid is determined by the location and dimension of the pathologic region to be treated. The duration of illumination period will be determined empirically, but is preferably a total or cumulative period of time between about 4 minutes and 72 hours. More preferably, the illumination period is between about 60 minutes and 148 hours. Most preferably, the illumination period is between about 2 hrs and 24 hours.
  • [0050]
    Preferably, the total fluence or energy of the light used for irradiating, as measured in Joules, is between about 30 Joules and about 25,000 Joules; more preferably, between about 100 Joules and about 20,000 Joules; and most preferably, between about 500 Joules and about 10,000 Joules. Light having a waveband corresponding at least in part with the characteristic light absorption waveband of said photosensitizing agent is used for irradiating the target tissue.
  • [0051]
    The intensity or power of the light used is measured in watts, with each Joule equal to one watt-sec. Therefore, the intensity of the light used for irradiating in the present invention may be substantially less than 500mW/cm2. Since the total fluence or amount of energy of the light in Joules is divided by the duration of total exposure time in seconds, the longer the amount of time the target is exposed to the irradiation, the greater the amount of total energy or fluence may be used without increasing the amount of the intensity of the light used. The present invention employs an amount of total fluence of irradiation that is sufficiently high to activate the photosensitizing agent, as applicable, with a concomitant reduction in the intensity of light and collateral or non-target specific tissue damage.
  • [0052]
    While not wishing to be limited by a theory, the inventor proposes that a targeted photosensitizing compound can be substantially and selectively photoactivated in the neovasculature target tissue within a therapeutically reasonable period of time and without excess toxicity or collateral damage to non-target tissues. A relatively low fluence can be used for a relatively long period of time in order to fully photoactivate the drug in order to insure adequate closure of the neovessels and vessel abnormalities.
  • [0053]
    Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.
  • EXAMPLES EXAMPLE 1 Treatment of Choroidal Neovasculature Lesions
  • [0054]
    A subject with choroidal neovascularization (CNV) from age-related macular generation is assessed using standard visual acuity testing, ophthalmic examination, color photographs and fluorescein angiograms (see Miller et al., Ach. Ophthal. vol. 117:1161-1173(1999)).
  • [0055]
    A photosensitizing agent, verteporfin, is conjugated using generally recognized methods in the art to a bindable fragment of the L19 antibody demonstrating high affinity to the ED-B of fibronectin (Birchler et al., Nature Biotech. 17: 984 (1999)). A therapeutically effective amount of the photosensitizing agent conjugate, approximately 5 mg/m2, is administered intravenously to the subject.
  • [0056]
    Following a period of approximately 1 hour, to permit the non-specifically bound photosensitizing agent conjugate to clear from collateral tissues, the subject is irradiated in one or more sessions for a total period of 10 minutes with 400 mW/cm2 of collimated LED light having a wavelength of 690 nm. This represents a total fluence of 240 Joules/cm2.
  • [0057]
    The entire lesion is treated with a single spot of the size as determined from a pretreatment angiogram. A margin of 300-500 μm may be added to ensure complete coverage of the lesion. A green non-activating observation light beam may be used for real-time observation and aiming during PDT.
  • [0058]
    Screening examinations may be performed during the first week immediately before treatment. Visual acuity is measured by standard refraction protocol using EDTRS criteria. A slit-lamp and a complete ophthalmoscopic exam is performed. Optic discs and maculae of both eyes are documented by stereo color photography. Stereo fluorescein angiography is performed with 10% sodium fluorescein. Frames are taken according to MPS standards. The photodynamic effects are monitored after 1, 4, and 12 weeks by means of visual acuity, ophthalmoscopy, fundus photography and stereo angiography. Angiograms are evaluated for angiographic occlusion and leakage after PDT.
  • EXAMPLE 2 Treatment of Retinal Neovasculature Lesions
  • [0059]
    According to Example 1, a liposomal benzoporphyrin derivative is conjugated to VEGF for use as a photosensitizer. A drug dose of 10 mg/m2 is administered to a subject with neovascular lesions in the retina of the eye via intravenous infusion over 10 minutes. The subject waits for a period of 6 hours to permit clearance from the tissues of non-specifically bound photosensitizing conjugate before illumination therapy is administered.
  • [0060]
    With the photosensitizer specifically localized to the retinal neovasculature lesions comprising VEGF receptor on the surface of the cells of the lesion, the subject is exposed to non-coherent light from a low power non-coherent broadband light source emitting at 690 nm. This illumination provides a radiant exposure of no more than 500 mW/cm2 for a period of approximately 20 minutes in one or more sessions producing a total fluence of illumination of about 600 Joules/cm2. Alternatively, coherent or laser light could be similarly employed. Photosensitization is performed with dilated pupils and topical anesthesia using a contact lens.
  • [0061]
    The entire lesion is treated with a single spot of the size as determined from a pretreatment angiogram. A margin of 300-500 μm is added to ensure complete coverage of the lesion. A green non-activating observation light beam is used for real-time observation and aiming during PDT. Screening examinations and visual acuity as disclosed in Example 1 is performed.
  • EXAMPLE 3 Treatment of Vascular Tumors of the Eye
  • [0062]
    Integrin ανβ3 integrin is expressed by vascular cells during angiogenesis and vascular remodeling and is highly expressed by endothelial cells undergoing angiogenesis in tumors. See Eliceiri, B. P. et al., J. Clin. Invest (1999) 103(9):1227-1230. Antibody elicited to ανβ3, such as LM609 (Vitaxin; Eliceiri et al.) is conjugated to a texaphyrin photosensitizing agent in a liposomal formulation. A drug dose of 25 mg/m2 is administered via intravenous infusion over 10 min. The photosensitizer localizes to the neovasculature lesions. The pupils are dilated to allow ambient light enter for photosensitization. Therefore, no slit lamp is needed for photosensitization and the subject may continue everyday activities while receiving PDT. The ambient light is used to photoactivate the photosensitizing agent for a total exposure time of 24 hours.
  • [0063]
    Screening examinations and visual acuity as disclosed in Example 1 is performed.
  • EXAMPLE 4 Treatment Choroidal Tumor of the Eye
  • [0064]
    Most ocular tumors metastasize from systemic origins in breast carcinoma in females, and bronchial carcinoma in males (Chen Y. R., et al., Bilateral choroidal metastases as the initial presentation of a small breast carcinoma: a case report, Chung Hua I Hsueh Tsa Chih (Taipei); 61(2):99-103 1998). Antibody elicited to carcinoembryonic antigen (CEA), which is associated with the choroidal tumor, is conjugated to a benzoporphyrin derivative photosensitizing agent in a liposomal formulation. A drug dose of 10 mg/m2 is administered via intravenous infusion over 10 min.
  • [0065]
    Additionally, the patient is administered the anti-ανβ3 antibody-texaphyrin conjugate at a drug dose of 25 mg/M2 as provided in Example 3.
  • [0066]
    After the texaphyrin photosensitizer conjugate localizes to the neovasculature lesion and the benzoporphyrin-anti-CEA conjugate localizes to the CEA tumor antigens, a period of 6 hours is permitted to pass to permit the unbound or nonspecifically bound photosensitizer conjugates to clear from the lesions.
  • [0067]
    A low power non-coherent broadband light source emitting at 690 nm is used as described in Example 2. The radiant exposure of 250 mW/cm2 is employed for approximately 1 hour over the course of one or more sessions to provide a total fluence of 900 J/cm2. Photosensitization is performed with dilated pupils and topical anesthesia using a contact lens. The entire lesion is treated with a single spot of the size as determined from a pretreatment angiogram. A margin of 300-500 μm is added to ensure complete coverage of the lesion. A green non-activating observation light beam is used for real-time observation and aiming during PDT. Screening examinations and visual acuity as disclosed in Example 1 is performed.
  • [0068]
    Although the present invention has been described in connection with the preferred form of practicing it, those of ordinary skill in the art will understand that many modifications can be made thereto within the scope of the claims that follow. Accordingly, it is not intended that the scope of the invention in any way be limited by the above description, but instead be determined entirely by reference to the claims that follow.

Claims (37)

    The invention claimed is:
  1. 1. A method to treat neovascular disease of the eye, comprising:
    administering a targeted photosensitizing compound which selectively binds to abnormal endothelium that lines or composes neovasculature tissue; and
    illuminating the neovasculature tissue with light for a period of time sufficient to activate the photosensitizing compound thereby causing damage to neovasculature tissue.
  2. 2. The method of claim 1, wherein said light is non-laser light.
  3. 3. The method of claim 1, wherein said light is laser light.
  4. 4. The method of claim 1, wherein the neovasculature tissue is present in retina, choroid or both.
  5. 5. The method of claim 1, wherein the treated neovascular disease is diabetic retinopathy.
  6. 6. The method of claim 1, wherein the treated neovascular disease is macular degeneration.
  7. 7. The method of claim 1, wherein the treated neovascular tissue arises from tumors of the eye.
  8. 8. The method of claim 1, wherein said tumors are benign.
  9. 9. The method of claim 1, wherein said tumors are malignant.
  10. 10. The method of claim 9, wherein said tumors are malignant uveal melanomas.
  11. 11. The method of claim 1, wherein the targeted photosensitizing compound is bound to a first component of a bindable pair and wherein a second component of the bindable pair is selected from the group consisting of: receptor present on abnormal endothelium; ligand bindable to receptor present on abnormal endothelium; antigen present on abnormal endothelium; and antibody bindable to antigen present on abnormal endothelium.
  12. 12. The method of claim 11, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  13. 13. The method of claim 11, wherein the ligand is selected from the group consisting of: the ED-B domain of fibronectin; antibody specifically elicited to ED-B domain of fibronectin; VEGF; VEGF receptor; and ανβ3 integrin receptor.
  14. 14. The method of claim 1, wherein the targeted photosensitizing compound is bound to a receptor composition that mimics a receptor present on abnormal endothelium.
  15. 15. The method of claim 14, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  16. 16. The method of claim 1, wherein the targeted photosensitizing compound is bound to a bi-specific antibody construct that further comprises both a ligand component and a receptor component.
  17. 17. The method of claim 16, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  18. 18. The method of claim 1, wherein the photosensitized neovasculature is illuminated for at least 4 minutes.
  19. 19. The method of claim 1, wherein the photosensitized neovasculature is illuminated for at least 20 minutes.
  20. 20. The method of claim 1, wherein the photosensitized neovasculature is illuminated for at least 1 hour.
  21. 21. The method of claim 1, wherein the photosensitized neovasculature is illuminated for at least 24 hours.
  22. 22. The method of claim 1, wherein the neovasculature tissue is treated with a total fluence of light irradiation from between about 240 J/cm2 to about 900 J/cm2.
  23. 23. The method of claim 1, wherein the non-laser light source is a light emitting diode.
  24. 24. The method of claim 1, wherein the non-laser light source is ambient light.
  25. 25. A method to treat neovascular disease of the eye, comprising:
    administering a first targeted photosensitizing compound which selectively binds to a first targeted tissue; and
    administering a second targeted photosensitizing compound which selectively binds to a second targeted tissue; and
    illuminating the first and second targeted tissues with non-laser light for a period of time sufficient to activate said first and second photosensitizing compounds thereby causing damage to said first and second targeted tissue.
  26. 26. The method of claim 25, wherein said first targeted tissues is abnormal endothelium that lines or composes neovasculature tissue; and said second targeted tissue is a tumor antigen.
  27. 27. The method of claim 26, wherein said first targeted photosensitizing compound comprises a ligand selected from the group consisting of: the ED-B domain of fibronectin; antibody specifically elicited to EDB domain of fibronectin; VEGF; VEGF receptor; and ανβ3 integrin receptor.
  28. 28. A kit to treat neovascular disease of the eye, comprising a targeted photosensitizing compound and instructions teaching a method according to claim 1.
  29. 29. A kit according to claim 28 wherein the targeted photosensitizing compound binds to a first component of a bindable pair and wherein a second component of the bindable pair is selected from the group consisting of: receptor present on abnormal endothelium; ligand bindable to receptor present on abnormal endothelium; antigen present on abnormal endothelium; and antibody bindable to antigen present on abnormal endothelium.
  30. 30. A kit according to claim 29, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  31. 31. A kit according to claim 29, wherein the ligand is selected from the group consisting of: the ED-B domain of fibronectin; antibody specifically elicited to ED-B domain of fibronectin; VEGF; VEGF receptor; and ανβ3 integrin receptor.
  32. 32. A kit according to claim 28, wherein the targeted photosensitizing compound binds to a receptor composition that mimics a receptor present on abnormal endothelium.
  33. 33. A kit according to claim 32, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  34. 34. A kit according to claim 28, wherein the targeted photosensitizing compound binds to a bi-specific antibody construct that further comprises both a ligand component and a receptor component.
  35. 35. A kit according to claim 34, wherein the targeted photosensitizing compound is incorporated into a liposomal preparation.
  36. 36. A method of instructing a person to treat neovascular disease of the eye, comprising instructing a person to conduct a method according to claim 1.
  37. 37. A method of instructing a person to treat neovascular disease of the eye, comprising instructing a person in the use of the kit of claim 28.
US09760362 2000-01-12 2001-01-12 Novel treatment for eye disease Abandoned US20020049247A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17568900 true 2000-01-12 2000-01-12
US09760362 US20020049247A1 (en) 2000-01-12 2001-01-12 Novel treatment for eye disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09760362 US20020049247A1 (en) 2000-01-12 2001-01-12 Novel treatment for eye disease
US11297880 US7320786B2 (en) 2000-01-12 2005-12-07 Photodynamic therapy treatment for eye disease

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09765867 Continuation-In-Part US20020092205A1 (en) 2001-01-12 2001-01-19 Snowboard boot with removable forward support
US11297880 Continuation US7320786B2 (en) 2000-01-12 2005-12-07 Photodynamic therapy treatment for eye disease
US11297880 Continuation-In-Part US7320786B2 (en) 2000-01-12 2005-12-07 Photodynamic therapy treatment for eye disease

Publications (1)

Publication Number Publication Date
US20020049247A1 true true US20020049247A1 (en) 2002-04-25

Family

ID=22641231

Family Applications (2)

Application Number Title Priority Date Filing Date
US09760362 Abandoned US20020049247A1 (en) 2000-01-12 2001-01-12 Novel treatment for eye disease
US11297880 Expired - Fee Related US7320786B2 (en) 2000-01-12 2005-12-07 Photodynamic therapy treatment for eye disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11297880 Expired - Fee Related US7320786B2 (en) 2000-01-12 2005-12-07 Photodynamic therapy treatment for eye disease

Country Status (5)

Country Link
US (2) US20020049247A1 (en)
EP (1) EP1267935A2 (en)
JP (1) JP2003519670A (en)
CA (1) CA2395567A1 (en)
WO (1) WO2001051087A3 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115902A1 (en) * 2001-02-22 2002-08-22 Dejuan Eugene Beta radiotherapy emitting surgical device and methods of use thereof
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030175282A1 (en) * 2000-02-10 2003-09-18 Miller Joan W. Methods and compositions for treating conditions of the eye
US20040122491A1 (en) * 2001-02-06 2004-06-24 Strong H. Andrew Reduced fluence rate PDT
US20050004510A1 (en) * 1999-01-15 2005-01-06 James Chen Noninvasive vascular therapy
US20050048044A1 (en) * 2002-07-02 2005-03-03 The Regents Of The University Of California Treatment for eye disorder
US20050277802A1 (en) * 2004-02-12 2005-12-15 Larsen Charles E Method and apparatus for intraocular brachytherapy
US20060111605A1 (en) * 2004-02-12 2006-05-25 Larsen Charles E Methods and apparatus for intraocular brachytherapy
US20060115428A1 (en) * 2004-10-14 2006-06-01 Andreas Menrad Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
US20060231107A1 (en) * 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
WO2007054120A1 (en) * 2005-11-09 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies
US20070118010A1 (en) * 2005-02-11 2007-05-24 Hillstead Richard A Methods and apparatus for intraocular brachytherapy
US20080124280A1 (en) * 2003-09-15 2008-05-29 Mousa Shaker A Thyroid Hormone Analogs and Methods of Use
US20100112079A1 (en) * 2003-09-15 2010-05-06 Ordway Research Institute, Inc. Thyroid Hormone Analogs and Methods of Use
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US20100255108A1 (en) * 2009-03-31 2010-10-07 Hung-Yun Lin Combination Treatment of Cancer With Cetuximab and Tetrac
US7820143B2 (en) 2002-06-27 2010-10-26 Health Research, Inc. Water soluble tetrapyrollic photosensitizers for photodynamic therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20110052715A1 (en) * 2009-06-17 2011-03-03 Davis Paul J Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110142941A1 (en) * 2006-12-22 2011-06-16 Davis Paul J Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US9272049B2 (en) 2005-09-16 2016-03-01 Nanopharmaceuticals Llc Methods of stimulating fat mobilization using a polymer conjugated polyphenol
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
RU2271222C2 (en) 2000-03-24 2006-03-10 Новартис Аг Improved method for treatment of neovascularization
US20020197700A1 (en) * 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
JP2005511576A (en) * 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ A method of treating ocular neovascular disease
US20030118657A1 (en) * 2001-12-04 2003-06-26 West Jennifer L. Treatment of disease states characterized by excessive or inappropriate angiogenesis
WO2004030588A3 (en) 2002-10-03 2004-08-05 James C Chen Excitation of photoreactive compounds in eye tissue
WO2004060373A1 (en) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. Therapeutic agent for wet age-related macular degeneration
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
GB2435211B (en) * 2006-01-25 2009-08-26 Alan Whitmore Drug delivery system
WO2008098300A1 (en) * 2007-02-14 2008-08-21 Opto Global Holdings Pty Ltd Method and system for control of therapeutic procedure
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2485765A2 (en) * 2009-10-09 2012-08-15 Board Of Regents The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
RU2467777C1 (en) * 2011-07-26 2012-11-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Method of photodynamic therapy of intraocular neoplasms
WO2017136486A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases

Citations (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18371A (en) * 1857-10-06 Improvement in sewing-machines
US30342A (en) * 1860-10-09 Improved packing-press
US44198A (en) * 1864-09-13 Improvement in vacuum apparatus for treating diseases
US44197A (en) * 1864-09-13 Improvement in he at-radiator
US114434A (en) * 1871-05-02 Improvement in dry-earth closets
US127224A (en) * 1872-05-28 Improvement in cotton-seed cleaners
US167033A (en) * 1875-08-24 Improvement in folding school-desks
US208249A (en) * 1878-09-24 Improvement in whip-rounding machines
US4521762A (en) * 1981-08-27 1985-06-04 Gte Automatic Electric Laboratories, Incorporated Integratable D/A converter
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4753958A (en) * 1985-02-07 1988-06-28 University Of Cal Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US4932934A (en) * 1982-09-27 1990-06-12 Health Research, Inc. Methods for treatment of tumors
US4957481A (en) * 1987-10-01 1990-09-18 U.S. Bioscience Photodynamic therapeutic technique
US4997639A (en) * 1989-11-27 1991-03-05 Nippon Petrochemicals Company, Limited Method for detecting cholesterol deposited in bodies of mammals
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5053006A (en) * 1988-04-19 1991-10-01 Watson Brant D Method for the permanent occlusion of arteries
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5298018A (en) * 1992-08-14 1994-03-29 Pdt Cardiovascular, Inc. Method for treating cardiovascular disease through adjunctive photodynamic therapy
US5308861A (en) * 1991-04-30 1994-05-03 Nippon Petrochemicals Company, Limited Therapeutic agent for treating atherosclerosis of mammals
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
US5430051A (en) * 1993-04-22 1995-07-04 Nippon Petrochemicals Company, Limited Treatment of arthritis using derivatives of porphorins
US5441531A (en) * 1993-10-18 1995-08-15 Dusa Pharmaceuticals Inc. Illuminator and methods for photodynamic therapy
US5484803A (en) * 1992-09-21 1996-01-16 Quadra Logic Technologies Inc. Transcutaneous in vivo activation of photosensitive agents in blood
US5484778A (en) * 1990-07-17 1996-01-16 University Hospitals Of Cleveland Phthalocyanine photosensitizers for photodynamic therapy and methods for their use
US5494793A (en) * 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5498710A (en) * 1994-04-22 1996-03-12 Health Research, Inc. Alkyl ether analogues of benzoporphyrin derivatives
US5500009A (en) * 1990-11-15 1996-03-19 Amron, Ltd. Method of treating herpes
US5514669A (en) * 1993-09-29 1996-05-07 Medical College Of Ohio Use of photodynamic therapy to treat prostatic tissue
US5534506A (en) * 1986-01-02 1996-07-09 University Of Toledo Use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5549660A (en) * 1990-11-15 1996-08-27 Amron, Ltd. Method of treating acne
US5556612A (en) * 1994-03-15 1996-09-17 The General Hospital Corporation Methods for phototherapeutic treatment of proliferative skin diseases
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5591847A (en) * 1994-05-23 1997-01-07 Health Research, Inc. Long wavelength absorbing photosensitizers related to purpurin-18, bacteriopurpurin-18 and related compounds with imide linkages
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5705518A (en) * 1992-11-20 1998-01-06 University Of British Columbia Method of activating photosensitive agents
US5715837A (en) * 1996-08-29 1998-02-10 Light Sciences Limited Partnership Transcutaneous electromagnetic energy transfer
US5741316A (en) * 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US5766234A (en) * 1996-03-07 1998-06-16 Light Sciences Limited Partnership Implanting and fixing a flexible probe for administering a medical therapy at a treatment site within a patient'body
US5782896A (en) * 1997-01-29 1998-07-21 Light Sciences Limited Partnership Use of a shape memory alloy to modify the disposition of a device within an implantable medical probe
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5814008A (en) * 1996-07-29 1998-09-29 Light Sciences Limited Partnership Method and device for applying hyperthermia to enhance drug perfusion and efficacy of subsequent light therapy
US5864035A (en) * 1996-03-08 1999-01-26 Health Research, Inc. Synthesis of isoimide of chlorins and bacteriochlorins and their use for diagnosis and treatment of cancer
US5865840A (en) * 1997-10-22 1999-02-02 Light Sciences Limited Partnership Enhancement of light activation effect by immune augmentation
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US5876427A (en) * 1997-01-29 1999-03-02 Light Sciences Limited Partnership Compact flexible circuit configuration
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5921244A (en) * 1997-06-11 1999-07-13 Light Sciences Limited Partnership Internal magnetic device to enhance drug therapy
US5929105A (en) * 1997-05-07 1999-07-27 Qltphoto Therapeutics, Inc. Ethylene glycol esters as photoactive agents
US5942534A (en) * 1996-10-10 1999-08-24 The General Hospital Corporation Photodynamic therapy for the treatment of osteoarthritis
US5944748A (en) * 1996-07-25 1999-08-31 Light Medicine, Inc. Photodynamic therapy apparatus and methods
US5945762A (en) * 1998-02-10 1999-08-31 Light Sciences Limited Partnership Movable magnet transmitter for inducing electrical current in an implanted coil
US5945439A (en) * 1992-08-17 1999-08-31 Qlt Phototherapeutics, Inc. Method for destroying or inhibiting growth of unwanted cells or tissues
US5952366A (en) * 1996-03-08 1999-09-14 Health Research, Inc. Alkyl ether analogs of chlorins having an N-substituted imide ring
US5955585A (en) * 1992-07-26 1999-09-21 Yeda Research And Development Co., Ltd. Catalytic condensation method for the preparation of chlorophyll and bacteriochlorophyll derivatives
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US6036941A (en) * 1995-07-19 2000-03-14 Consiglio Nazionale Delle Ricerche Fluorogenic substrates for diagnosis and photodynamic treatment of tumors
US6048359A (en) * 1997-08-25 2000-04-11 Advanced Photodynamic Technologies, Inc. Spatial orientation and light sources and method of using same for medical diagnosis and photodynamic therapy
US6058937A (en) * 1997-07-18 2000-05-09 Miravant Systems, Inc. Photodynamic Therapy of highly vascularized tissue
US6080160A (en) * 1996-12-04 2000-06-27 Light Sciences Limited Partnership Use of shape memory alloy for internally fixing light emitting device at treatment site
US6083485A (en) * 1994-12-07 2000-07-04 Institut Fur Diagnostikforschung Gmbh Near infrared radiation in-vivo diagnostic methods and dyes
US6090788A (en) * 1997-07-28 2000-07-18 Dermatolazer Technologies Ltd. Phototherapy based method for treating pathogens and composition for effecting same
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6187030B1 (en) * 1996-09-04 2001-02-13 Mbg Technologies, Inc. Photodynamic therapy method
US6210425B1 (en) * 1999-07-08 2001-04-03 Light Sciences Corporation Combined imaging and PDT delivery system
US6217869B1 (en) * 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US6238426B1 (en) * 1999-07-19 2001-05-29 Light Sciences Corporation Real-time monitoring of photodynamic therapy over an extended time
US6270749B1 (en) * 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6273904B1 (en) * 1999-03-02 2001-08-14 Light Sciences Corporation Polymer battery for internal light device
US20020010500A1 (en) * 1998-06-24 2002-01-24 Light Sciences Corporation Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy
US6344050B1 (en) * 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US20030018371A1 (en) * 1999-01-15 2003-01-23 Light Sciences Corporation Compositions and methods for the treatment of metabolic bone disorders and bone metastases
US20030109813A1 (en) * 1999-01-15 2003-06-12 James Chen Energy-activated targeted cancer therapy
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US20040044197A1 (en) * 2002-06-27 2004-03-04 Pandey Ravindra K. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US20040044198A1 (en) * 2002-07-02 2004-03-04 Pandey Ravindra K. Efficient synthesis of pyropheophorbide a and its derivatives

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4374925A (en) 1978-11-24 1983-02-22 Syva Company Macromolecular environment control in specific receptor assays
US4251762A (en) * 1979-03-16 1981-02-17 Moog Inc. Armature position detector
EP0220601B1 (en) * 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4878891A (en) 1987-06-25 1989-11-07 Baylor Research Foundation Method for eradicating infectious biological contaminants in body tissues
US5503637A (en) 1987-06-26 1996-04-02 Light Sciences, Inc. Apparatus for producing and delivering high-intensity light to a subject
US5919217A (en) 1987-12-08 1999-07-06 Medic-Light, Inc. Portable phototherapy unit
US4823244A (en) 1988-01-29 1989-04-18 Niagara Medical Innovations Inc. Light source assembly
US5026367A (en) 1988-03-18 1991-06-25 Cardiovascular Laser Systems, Inc. Laser angioplasty catheter and a method for use thereof
US4961920A (en) 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5238940A (en) 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5869457A (en) 1991-03-11 1999-02-09 Rijksuniversiteit Te Groningen Modified proteins and their use for controlling viral infections
US5263925A (en) 1991-07-22 1993-11-23 Gilmore Jr Thomas F Photopheresis blood treatment
US5222795A (en) 1991-12-26 1993-06-29 Light Sciences, Inc. Controlled light extraction from light guides and fibers
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5608060A (en) 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
DK0653066T3 (en) 1992-07-31 1998-09-23 Dade Behring Marburg Gmbh Photoactivatable chemiluminescent matrices
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
GB2272278B (en) 1992-10-23 1997-04-09 Cancer Res Campaign Tech Light source
US5368841A (en) * 1993-02-11 1994-11-29 The General Hospital Corporation Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5445608A (en) 1993-08-16 1995-08-29 James C. Chen Method and apparatus for providing light-activated therapy
EP0716746B1 (en) 1993-09-03 1999-03-17 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5420768A (en) 1993-09-13 1995-05-30 Kennedy; John Portable led photocuring device
US5913834A (en) 1993-11-04 1999-06-22 Francais; Caramia System for imparting sensory effects across a mother's abdomen to a fetus and monitoring effects on the fetus
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5707401A (en) 1994-03-10 1998-01-13 Esc Medical Systems, Ltd. Apparatus for an efficient photodynamic treatment
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5851225A (en) * 1994-03-18 1998-12-22 Spectra Science Corporation Photoemitting catheters and other structures suitable for use in photo-dynamic therapy and other applications
US5616140A (en) 1994-03-21 1997-04-01 Prescott; Marvin Method and apparatus for therapeutic laser treatment
EP0673627B1 (en) * 1994-03-23 2000-01-05 Hamamatsu Photonics K.K. Catheter with optical fiber
US5456661A (en) 1994-03-31 1995-10-10 Pdt Cardiovascular Catheter with thermally stable balloon
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5746494A (en) 1994-11-22 1998-05-05 Asahi Kogaku Kogyo Kabushiki Kaisha Illuminating apparatus of endoscope
US5576013A (en) 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
FR2732094A1 (en) 1995-03-22 1996-09-27 Philips Eclairage Light generator for optical fibers
US5735817A (en) 1995-05-19 1998-04-07 Shantha; T. R. Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures
US5571152A (en) 1995-05-26 1996-11-05 Light Sciences Limited Partnership Microminiature illuminator for administering photodynamic therapy
US5912257A (en) 1995-09-06 1999-06-15 The Research Foundation Of State University Of New York Two-photon upconverting dyes and applications
JP2961074B2 (en) 1995-09-06 1999-10-12 明治製菓株式会社 Shinsei vascular occlusion agent for photodynamic therapy
US5824080A (en) * 1995-09-28 1998-10-20 The General Hospital Corporation Photochemistry for the preparation of biologic grafts--allografts and xenografts
US5776175A (en) 1995-09-29 1998-07-07 Esc Medical Systems Ltd. Method and apparatus for treatment of cancer using pulsed electromagnetic radiation
US5835648A (en) 1996-03-07 1998-11-10 Miravant Systems, Inc. Surface illuminator for photodynamic therapy
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US5797868A (en) 1996-07-25 1998-08-25 Cordis Corporation Photodynamic therapy balloon catheter
US5904147A (en) 1996-08-16 1999-05-18 University Of Massachusetts Intravascular catheter and method of controlling hemorrhage during minimally invasive surgery
US5702432A (en) 1996-10-03 1997-12-30 Light Sciences Limited Partnership Intracorporeal light treatment of blood
US5832931A (en) * 1996-10-30 1998-11-10 Photogen, Inc. Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
US5829448A (en) * 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US5746495A (en) 1997-02-05 1998-05-05 Klamm; Thomas L. Portable work light with optical fiber adapter
US5817048A (en) 1997-03-20 1998-10-06 Brown University Research Foundation Ultrasonic alternative to laser-based photodynamic therapy
US5827186A (en) 1997-04-11 1998-10-27 Light Sciences Limited Partnership Method and PDT probe for minimizing CT and MRI image artifacts
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US20030030342A1 (en) * 1998-02-10 2003-02-13 Chen James C. Contactless energy transfer apparatus
US6162242A (en) * 1999-01-21 2000-12-19 Peyman; Gholam A. Selective photodynamic treatment
JP3463673B2 (en) * 2001-04-11 2003-11-05 日産自動車株式会社 Map data distribution device and the map data distribution method

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18371A (en) * 1857-10-06 Improvement in sewing-machines
US30342A (en) * 1860-10-09 Improved packing-press
US44198A (en) * 1864-09-13 Improvement in vacuum apparatus for treating diseases
US44197A (en) * 1864-09-13 Improvement in he at-radiator
US114434A (en) * 1871-05-02 Improvement in dry-earth closets
US127224A (en) * 1872-05-28 Improvement in cotton-seed cleaners
US167033A (en) * 1875-08-24 Improvement in folding school-desks
US208249A (en) * 1878-09-24 Improvement in whip-rounding machines
US4521762A (en) * 1981-08-27 1985-06-04 Gte Automatic Electric Laboratories, Incorporated Integratable D/A converter
US4932934A (en) * 1982-09-27 1990-06-12 Health Research, Inc. Methods for treatment of tumors
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4753958A (en) * 1985-02-07 1988-06-28 University Of Cal Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins
US5534506A (en) * 1986-01-02 1996-07-09 University Of Toledo Use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5494793A (en) * 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5399583A (en) * 1987-01-20 1995-03-21 The University Of British Columbia Method of treating skin diseases
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4957481A (en) * 1987-10-01 1990-09-18 U.S. Bioscience Photodynamic therapeutic technique
US5053006A (en) * 1988-04-19 1991-10-01 Watson Brant D Method for the permanent occlusion of arteries
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5459159A (en) * 1988-07-20 1995-10-17 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
US5314905A (en) * 1988-07-20 1994-05-24 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US4997639A (en) * 1989-11-27 1991-03-05 Nippon Petrochemicals Company, Limited Method for detecting cholesterol deposited in bodies of mammals
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5484778A (en) * 1990-07-17 1996-01-16 University Hospitals Of Cleveland Phthalocyanine photosensitizers for photodynamic therapy and methods for their use
US5549660A (en) * 1990-11-15 1996-08-27 Amron, Ltd. Method of treating acne
US5500009A (en) * 1990-11-15 1996-03-19 Amron, Ltd. Method of treating herpes
US5308861A (en) * 1991-04-30 1994-05-03 Nippon Petrochemicals Company, Limited Therapeutic agent for treating atherosclerosis of mammals
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US6100290A (en) * 1992-05-27 2000-08-08 Qlt Inc. Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
US6217869B1 (en) * 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5955585A (en) * 1992-07-26 1999-09-21 Yeda Research And Development Co., Ltd. Catalytic condensation method for the preparation of chlorophyll and bacteriochlorophyll derivatives
US5298018A (en) * 1992-08-14 1994-03-29 Pdt Cardiovascular, Inc. Method for treating cardiovascular disease through adjunctive photodynamic therapy
US5945439A (en) * 1992-08-17 1999-08-31 Qlt Phototherapeutics, Inc. Method for destroying or inhibiting growth of unwanted cells or tissues
US5736563A (en) * 1992-09-21 1998-04-07 Quadra Logic Technologies, Inc. Transcutaneous in vivo activation of photosensitive agents in blood
US5484803A (en) * 1992-09-21 1996-01-16 Quadra Logic Technologies Inc. Transcutaneous in vivo activation of photosensitive agents in blood
US5770619A (en) * 1992-11-20 1998-06-23 University Of British Columbia Method of activating photosensitive agents
US5705518A (en) * 1992-11-20 1998-01-06 University Of British Columbia Method of activating photosensitive agents
US5567409A (en) * 1993-04-22 1996-10-22 Nippon Petrochemicals Company, Ltd. Method and medical agent for diagnosis of arthritis
US5430051A (en) * 1993-04-22 1995-07-04 Nippon Petrochemicals Company, Limited Treatment of arthritis using derivatives of porphorins
US5514669A (en) * 1993-09-29 1996-05-07 Medical College Of Ohio Use of photodynamic therapy to treat prostatic tissue
US5441531A (en) * 1993-10-18 1995-08-15 Dusa Pharmaceuticals Inc. Illuminator and methods for photodynamic therapy
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5556612A (en) * 1994-03-15 1996-09-17 The General Hospital Corporation Methods for phototherapeutic treatment of proliferative skin diseases
US5498710A (en) * 1994-04-22 1996-03-12 Health Research, Inc. Alkyl ether analogues of benzoporphyrin derivatives
US5591847A (en) * 1994-05-23 1997-01-07 Health Research, Inc. Long wavelength absorbing photosensitizers related to purpurin-18, bacteriopurpurin-18 and related compounds with imide linkages
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US6083485A (en) * 1994-12-07 2000-07-04 Institut Fur Diagnostikforschung Gmbh Near infrared radiation in-vivo diagnostic methods and dyes
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6036941A (en) * 1995-07-19 2000-03-14 Consiglio Nazionale Delle Ricerche Fluorogenic substrates for diagnosis and photodynamic treatment of tumors
US5766234A (en) * 1996-03-07 1998-06-16 Light Sciences Limited Partnership Implanting and fixing a flexible probe for administering a medical therapy at a treatment site within a patient'body
US5800478A (en) * 1996-03-07 1998-09-01 Light Sciences Limited Partnership Flexible microcircuits for internal light therapy
US5864035A (en) * 1996-03-08 1999-01-26 Health Research, Inc. Synthesis of isoimide of chlorins and bacteriochlorins and their use for diagnosis and treatment of cancer
US5952366A (en) * 1996-03-08 1999-09-14 Health Research, Inc. Alkyl ether analogs of chlorins having an N-substituted imide ring
US5944748A (en) * 1996-07-25 1999-08-31 Light Medicine, Inc. Photodynamic therapy apparatus and methods
US5814008A (en) * 1996-07-29 1998-09-29 Light Sciences Limited Partnership Method and device for applying hyperthermia to enhance drug perfusion and efficacy of subsequent light therapy
US5715837A (en) * 1996-08-29 1998-02-10 Light Sciences Limited Partnership Transcutaneous electromagnetic energy transfer
US6187030B1 (en) * 1996-09-04 2001-02-13 Mbg Technologies, Inc. Photodynamic therapy method
US6107466A (en) * 1996-09-19 2000-08-22 The General Hospital Corporation Acceleration of wound healing by photodynamic therapy
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5942534A (en) * 1996-10-10 1999-08-24 The General Hospital Corporation Photodynamic therapy for the treatment of osteoarthritis
US5741316A (en) * 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US6080160A (en) * 1996-12-04 2000-06-27 Light Sciences Limited Partnership Use of shape memory alloy for internally fixing light emitting device at treatment site
US6270749B1 (en) * 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US5876427A (en) * 1997-01-29 1999-03-02 Light Sciences Limited Partnership Compact flexible circuit configuration
US5782896A (en) * 1997-01-29 1998-07-21 Light Sciences Limited Partnership Use of a shape memory alloy to modify the disposition of a device within an implantable medical probe
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
US5929105A (en) * 1997-05-07 1999-07-27 Qltphoto Therapeutics, Inc. Ethylene glycol esters as photoactive agents
US5921244A (en) * 1997-06-11 1999-07-13 Light Sciences Limited Partnership Internal magnetic device to enhance drug therapy
US6058937A (en) * 1997-07-18 2000-05-09 Miravant Systems, Inc. Photodynamic Therapy of highly vascularized tissue
US6090788A (en) * 1997-07-28 2000-07-18 Dermatolazer Technologies Ltd. Phototherapy based method for treating pathogens and composition for effecting same
US6048359A (en) * 1997-08-25 2000-04-11 Advanced Photodynamic Technologies, Inc. Spatial orientation and light sources and method of using same for medical diagnosis and photodynamic therapy
US5865840A (en) * 1997-10-22 1999-02-02 Light Sciences Limited Partnership Enhancement of light activation effect by immune augmentation
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US5945762A (en) * 1998-02-10 1999-08-31 Light Sciences Limited Partnership Movable magnet transmitter for inducing electrical current in an implanted coil
US6092531A (en) * 1998-02-10 2000-07-25 Light Sciences Limited Partnership Movable magnet transmitter for inducing electrical current in an implanted coil
US20020010500A1 (en) * 1998-06-24 2002-01-24 Light Sciences Corporation Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6344050B1 (en) * 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030109813A1 (en) * 1999-01-15 2003-06-12 James Chen Energy-activated targeted cancer therapy
US20030018371A1 (en) * 1999-01-15 2003-01-23 Light Sciences Corporation Compositions and methods for the treatment of metabolic bone disorders and bone metastases
US6273904B1 (en) * 1999-03-02 2001-08-14 Light Sciences Corporation Polymer battery for internal light device
US6210425B1 (en) * 1999-07-08 2001-04-03 Light Sciences Corporation Combined imaging and PDT delivery system
US6238426B1 (en) * 1999-07-19 2001-05-29 Light Sciences Corporation Real-time monitoring of photodynamic therapy over an extended time
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
US20040044197A1 (en) * 2002-06-27 2004-03-04 Pandey Ravindra K. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US20040044198A1 (en) * 2002-07-02 2004-03-04 Pandey Ravindra K. Efficient synthesis of pyropheophorbide a and its derivatives

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004510A1 (en) * 1999-01-15 2005-01-06 James Chen Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20050196401A1 (en) * 1999-01-15 2005-09-08 James Chen Energy-activated targeted cancer therapy
US20040215292A1 (en) * 1999-01-15 2004-10-28 James Chen Photodynamic treatment of targeted cells
US7767208B2 (en) 1999-01-15 2010-08-03 Light Sciences Oncology, Inc. Noninvasive vascular therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20030175282A1 (en) * 2000-02-10 2003-09-18 Miller Joan W. Methods and compositions for treating conditions of the eye
US20030185834A1 (en) * 2000-02-10 2003-10-02 Miller Joan W. Methods and compositions for treating conditions of the eye
US7125542B2 (en) 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20090286743A1 (en) * 2000-02-10 2009-11-19 Miller Joan W Methods and Compositions for Treating Conditions of the Eye
US20040122491A1 (en) * 2001-02-06 2004-06-24 Strong H. Andrew Reduced fluence rate PDT
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
US20020115902A1 (en) * 2001-02-22 2002-08-22 Dejuan Eugene Beta radiotherapy emitting surgical device and methods of use thereof
US8100818B2 (en) 2001-02-22 2012-01-24 TDH Partners, Inc. Beta radiotherapy emitting surgical device and methods of use thereof
US20050177019A1 (en) * 2001-02-22 2005-08-11 Dejuan Eugene Jr. Ophthalmic treatment apparatus
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
US20060142629A1 (en) * 2001-02-22 2006-06-29 Dejuan Eugene Jr Intraocular radiotherapy treatment for macular degeneration
US20070265485A1 (en) * 2001-02-22 2007-11-15 Dejuan Eugene Jr Beta radiotherapy emitting surgical device and methods of use thereof
US7820143B2 (en) 2002-06-27 2010-10-26 Health Research, Inc. Water soluble tetrapyrollic photosensitizers for photodynamic therapy
USRE43274E1 (en) 2002-06-27 2012-03-27 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US8298521B2 (en) 2002-07-02 2012-10-30 The Regents Of The University Of California Treatment for eye disorder
US20050048044A1 (en) * 2002-07-02 2005-03-03 The Regents Of The University Of California Treatment for eye disorder
US7381404B2 (en) * 2002-07-02 2008-06-03 The Regents Of The University Of California Treatment for dry macular degeneration
US20080286255A1 (en) * 2002-07-02 2008-11-20 The Regents Of The University Of California Treatment for eye disorder
US20060231107A1 (en) * 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
US20100112079A1 (en) * 2003-09-15 2010-05-06 Ordway Research Institute, Inc. Thyroid Hormone Analogs and Methods of Use
US9750709B2 (en) 2003-09-15 2017-09-05 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9579300B2 (en) 2003-09-15 2017-02-28 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8518451B2 (en) 2003-09-15 2013-08-27 Albany College of Pharmacy and Health Services Thyroid hormone analogs and methods of use
US20080124280A1 (en) * 2003-09-15 2008-05-29 Mousa Shaker A Thyroid Hormone Analogs and Methods of Use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US20070055089A1 (en) * 2004-02-12 2007-03-08 Larsen Charles E Methods and apparatus for intraocular brachytherapy
US20100268013A1 (en) * 2004-02-12 2010-10-21 Larsen Charles E Methods and apparatus for intraocular brachytherapy
US7803102B2 (en) 2004-02-12 2010-09-28 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US20110004045A1 (en) * 2004-02-12 2011-01-06 Larsen Charles E Methods And Apparatus for Intraocular Brachytherapy
US8365721B2 (en) 2004-02-12 2013-02-05 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US7744520B2 (en) 2004-02-12 2010-06-29 Neovista, Inc. Method and apparatus for intraocular brachytherapy
US7951060B2 (en) 2004-02-12 2011-05-31 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US20060111605A1 (en) * 2004-02-12 2006-05-25 Larsen Charles E Methods and apparatus for intraocular brachytherapy
US20050277802A1 (en) * 2004-02-12 2005-12-15 Larsen Charles E Method and apparatus for intraocular brachytherapy
US20060115428A1 (en) * 2004-10-14 2006-06-01 Andreas Menrad Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
US7803103B2 (en) 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US20070118010A1 (en) * 2005-02-11 2007-05-24 Hillstead Richard A Methods and apparatus for intraocular brachytherapy
US8292795B2 (en) 2005-02-11 2012-10-23 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9272049B2 (en) 2005-09-16 2016-03-01 Nanopharmaceuticals Llc Methods of stimulating fat mobilization using a polymer conjugated polyphenol
WO2007054120A1 (en) * 2005-11-09 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies
US20110142941A1 (en) * 2006-12-22 2011-06-16 Davis Paul J Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof
US9289395B2 (en) 2006-12-22 2016-03-22 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US20100255108A1 (en) * 2009-03-31 2010-10-07 Hung-Yun Lin Combination Treatment of Cancer With Cetuximab and Tetrac
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US9839614B2 (en) 2009-06-17 2017-12-12 Nanopharmaceuticals, Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110052715A1 (en) * 2009-06-17 2011-03-03 Davis Paul J Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells

Also Published As

Publication number Publication date Type
WO2001051087A2 (en) 2001-07-19 application
WO2001051087A3 (en) 2002-05-10 application
CA2395567A1 (en) 2001-07-19 application
JP2003519670A (en) 2003-06-24 application
EP1267935A2 (en) 2003-01-02 application
US20060088530A1 (en) 2006-04-27 application
US7320786B2 (en) 2008-01-22 grant

Similar Documents

Publication Publication Date Title
Regula et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.
Fisher et al. Clinical and preclinical photodynamic therapy
Senge et al. Temoporfin (Foscan®, 5, 10, 15, 20‐tetra (m‐hydroxyphenyl) chlorin)—a second‐generation photosensitizer
Allison et al. Oncologic photodynamic therapy photosensitizers: a clinical review
US5211938A (en) Method of detection of malignant and non-malignant lesions by photochemotherapy of protoporphyrin IX percursors
Schmidt-Erfurth et al. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas
Brown et al. The present and future role of photodynamic therapy in cancer treatment
US6058937A (en) Photodynamic Therapy of highly vascularized tissue
Dougherty et al. Photodynamic therapy
Allison et al. Photosensitizers in clinical PDT
Michels et al. Sequence of early vascular events after photodynamic therapy
Barbazetto et al. Photodynamic therapy of choroidal hemangioma: two case reports
Reinke et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey1
Cuomo et al. Liposome-delivered Si (IV)-naphthalocyanine as a photodynamic sensitiser for experimental tumours: pharmacokinetic and phototherapeutic studies
US5368841A (en) Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
US5736563A (en) Transcutaneous in vivo activation of photosensitive agents in blood
Krauss et al. Lasers in ophthalmology
Peng et al. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy
Pinthus et al. Photodynamic therapy for urological malignancies: past to current approaches
Schmidt-Erfurth et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin
Hasan et al. Photodynamic therapy of cancer
Costa et al. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization
Chen et al. Vascular and cellular targeting for photodynamic therapy
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
Dolmans et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIGHT SCIENCES CORPORATION, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEN, JAMES C.;REEL/FRAME:012053/0197

Effective date: 20010530

AS Assignment

Owner name: LIGHT SCIENCES CORPORATION, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEN, JAMES;REEL/FRAME:012670/0344

Effective date: 20020114